Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 266


Acute psychosis related to use of trimethoprim/sulfamethoxazole in the treatment of HIV-infected patients with Pneumocystis jirovecii pneumonia: a multicentre, retrospective study.

Lee KY, Huang CH, Tang HJ, Yang CJ, Ko WC, Chen YH, Lee YC, Hung CC.

J Antimicrob Chemother. 2012 Nov;67(11):2749-54. doi: 10.1093/jac/dks283. Epub 2012 Jul 20.


Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia.

Yang JJ, Huang CH, Liu CE, Tang HJ, Yang CJ, Lee YC, Lee KY, Tsai MS, Lin SW, Chen YH, Lu PL, Hung CC.

PLoS One. 2014 Sep 3;9(9):e106141. doi: 10.1371/journal.pone.0106141. eCollection 2014.


'Septrin psychosis' among renal transplant patients with Pneumocystis jirovecii pneumonia.

Walker LE, Thomas S, McBride C, Howse M, Turtle LC, Vivancos R, Beeching NJ, Beadsworth MB.

J Antimicrob Chemother. 2011 May;66(5):1117-9. doi: 10.1093/jac/dkr050. Epub 2011 Feb 28.


Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients.

Thomas M, Rupali P, Woodhouse A, Ellis-Pegler R.

Scand J Infect Dis. 2009;41(11-12):862-8. doi: 10.3109/00365540903214256.


Dihydropteroate synthase (DHPS) gene mutation study in HIV-Infected Indian patients with Pneumocystis jirovecii pneumonia.

Tyagi AK, Mirdha BR, Luthra K, Guleria R, Mohan A, Singh UB, Samantaray JC, Dar L, Iyer VK, Chaudhry R.

J Infect Dev Ctries. 2010 Nov 24;4(11):761-6.


High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS.

Chang HM, Tsai HC, Lee SS, Kunin C, Lin PC, Wann SR, Chen YS.

J Chin Med Assoc. 2016 Jun;79(6):314-9. doi: 10.1016/j.jcma.2016.01.007. Epub 2016 Mar 22.


Severe septic-shock like reaction to co-trimoxazole in an HIV-positive man.

Scourfield A, Tan LK, Nelson M.

Int J STD AIDS. 2010 Jul;21(7):521-3. doi: 10.1258/ijsa.2010.010079.


Pneumocystis jirovecii pneumonia in patients with and without human immunodeficiency virus infection.

Su YS, Lu JJ, Perng CL, Chang FY.

J Microbiol Immunol Infect. 2008 Dec;41(6):478-82.


Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study.

Helweg-Larsen J, Benfield T, Atzori C, Miller RF.

J Antimicrob Chemother. 2009 Dec;64(6):1282-90. doi: 10.1093/jac/dkp372. Epub 2009 Oct 26.


Effects of Sulfamethoxazole-Trimethoprim on Airway Colonization with Pneumocystis jirovecii.

Kushima H, Ishii H, Tokimatsu I, Umeki K, Sato T, Kadota J.

Jpn J Infect Dis. 2016 May 20;69(3):252-5. doi: 10.7883/yoken.JJID.2014.546. Epub 2015 Aug 7.


Deterioration of the immune response induced by sulfamethoxazole-trimethoprim in a rheumatoid arthritis patient with Pneumocystis jirovecii pneumonia.

Gochi M, Takayanagi N, Ishiguro T, Miyahara Y, Yanagisawa T, Shimizu Y, Sugita Y.

Intern Med. 2014;53(11):1137-41. Epub 2014 Jun 1.


Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients.

Tu GW, Ju MJ, Xu M, Rong RM, He YZ, Xue ZG, Zhu TY, Luo Z.

Nephrology (Carlton). 2013 Nov;18(11):736-42. doi: 10.1111/nep.12133. Review.


Early use of corticosteroids in infants with a clinical diagnosis of Pneumocystis jiroveci pneumonia in Malawi: a double-blind, randomised clinical trial.

Newberry L, O'Hare B, Kennedy N, Selman A, Omar S, Dawson P, Stevenson K, Nishihara Y, Lissauer S, Molyneux E.

Paediatr Int Child Health. 2017 May;37(2):121-128. doi: 10.1080/20469047.2016.1260891. Epub 2017 Feb 1.


High Prevalence of Pneumocystis jirovecii Dihydropteroate Synthase Gene Mutations in Patients with a First Episode of Pneumocystis Pneumonia in Santiago, Chile, and Clinical Response to Trimethoprim-Sulfamethoxazole Therapy.

Ponce CA, Chabé M, George C, Cárdenas A, Durán L, Guerrero J, Bustamante R, Matos O, Huang L, Miller RF, Vargas SL.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01290-16. doi: 10.1128/AAC.01290-16. Print 2017 Feb.


A systematic review of two different trimetoprim-sulfamethoxazole regimens used to prevent Pneumocystis jirovecii and no prophylaxis at all in transplant recipients: appraising the evidence.

Di Cocco P, Orlando G, Bonanni L, D'Angelo M, Clemente K, Greco S, Gravante G, Madeddu F, Scelzo C, Famulari A, Pisani F.

Transplant Proc. 2009 May;41(4):1201-3. doi: 10.1016/j.transproceed.2009.03.004. Review.


[Pneumocystis pneumonia in a renal transplant recipient].

Özkoç S, İnceboz T, Sıfıl A, Tuncay S, Akisü Ç.

Turkiye Parazitol Derg. 2010;34(4):186-9. doi: 10.5152/tpd.2010.10. Turkish.


[Pneumocystis jirovecii pneumonia in HIV-infected patients].

De Castro N, Scemla A, Gallien S, Molina JM.

Rev Mal Respir. 2012 Jun;29(6):793-802. doi: 10.1016/j.rmr.2011.10.975. Epub 2012 May 14. Review. French.


Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases.

Hanses F, Zierhut S, Schölmerich J, Salzberger B, Wrede CE.

Int J Infect Dis. 2009 Nov;13(6):e467-9. doi: 10.1016/j.ijid.2008.12.016. Epub 2009 Mar 18.


Newly formed cystic lesions for the development of pneumomediastinum in Pneumocystis jirovecii pneumonia.

Cho JY, Kim DM, Kwon YE, Yoon SH, Lee SI.

BMC Infect Dis. 2009 Oct 18;9:171. doi: 10.1186/1471-2334-9-171.

Supplemental Content

Support Center